Sugi Predict

Sugi Predict / Compounds / Macimorelin

Macimorelin

Macimorelin

SCHEMBL1743598

CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NC(Cc1c[nH]c2ccccc12)NC=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GHSR

The experimentally established mechanism targets of Macimorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ GHSR known ✓ Q92847 14/20 1.00
▸ OPRM1 P35372 1/20 1.00
▸ ACE P12821 2/20 0.55
▸ ALOX15 P16050 1/20 0.49
▸ CTSL P07711 1/20 0.48
▸ CTSS P25774 1/20 0.48
▸ CTSK P43235 1/20 0.48
▸ MMP9 P14780 1/20 0.48
▸ MMP8 P22894 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Macimorelin SCHEMBL15533638 1.00 GHSR (1.00) GHSROPRM1ACEALOX15CTSL
Macimorelin SCHEMBL1984708 1.00 GHSR (1.00) GHSROPRM1ACEALOX15CTSL
Macimorelin SCHEMBL29359318 0.97 GHSR (0.94) GHSROPRM1ACEALOX15CTSL
SCHEMBL736883 0.94 GHSR (0.88) GHSROPRM1ACEALOX15
SCHEMBL737074 0.94 GHSR (0.88) GHSROPRM1ACEALOX15
SCHEMBL737019 0.92 GHSR (0.85) GHSROPRM1ACEALOX15CTSL
SCHEMBL736951 0.92 GHSR (0.85) GHSROPRM1ACEALOX15CTSL
SCHEMBL737619 0.90 GHSR (0.81) GHSROPRM1ACE
SCHEMBL737877 0.90 GHSR (0.81) GHSROPRM1ACE
SCHEMBL22353244 0.88 GHSR (0.78) GHSROPRM1ACECTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2913063-B1 THERAPEUTIC AGENT FOR USE IN TREATING AMYOTROPHIC LATERAL SCLEROSIS DAIICHI SANKYO CO LTD (JP) 2019-09-11 — — EP disclosed
EP-2387440-B1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2016-11-09 — — EP disclosed
EP-2323970-B1 CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2016-04-20 — — EP disclosed
US-20150265680-A1 THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-09-24 — — US disclosed
EP-2913063-A1 THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-09-02 — — EP disclosed
EP-2531490-B1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2014-10-15 — — EP disclosed
US-8835444-B2 Cyclohexyl amide derivatives as CRF receptor antagonists NOVARTIS AG (CH) 2014-09-16 — — US disclosed
EP-2531510-B1 PYRAZOLO[5,1B]OXAZOLE DERIVATIVES AS CRF-1 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2014-07-23 — — EP disclosed
US-20140088105-A1 Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists NOVARTIS AG (CH) 2014-03-27 — — US disclosed
US-8614213-B2 Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists NOVARTIS AG (CH) 2013-12-24 — — US disclosed
WO-2011095450-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-11 — — WO disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-20110190360-A1 PYRAZOLO[5,1B]OXAZOLE DERIVATIVES AS CRF-1 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-04 — — US disclosed
WO-2011092293-A2 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-04 — — WO disclosed
WO-2011092290-A1 PYRAZOLO[5,1B]OXAZOLE DERIVATIVES AS CRF-1 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-04 — — WO disclosed
US-20110152261-A1 Organic compounds NOVARTIS AG (CH) 2011-06-23 — — US disclosed
EP-2323970-A1 CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS Novartis AG (CH) 2011-05-25 — — EP disclosed
US-20100197705-A1 Quinazolinone Derivatives Useful as Vanilloid Antagonists CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2010-08-05 — — US disclosed
US-20100035898-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035874-A1 Organic compounds CRH, CRHR1, CRHR2 GHSR 86/4885OPRM1 19/4885ACE 305/4885
US-20100035898-A1 Organic compounds CRH, CRHR1, CRHR2 GHSR 39/4885OPRM1 17/4885ACE 264/4885
US-20110152261-A1 Organic compounds CRH, CRHR1, CRHR2 GHSR 36/4885OPRM1 15/4885ACE 283/4885
US-20110190360-A1 PYRAZOLO[5,1B]OXAZOLE DERIVATIVES AS CRF-1 RECEPTOR ANTAGONISTS CRHR1, CRH, CRHR2 GHSR 45/4885OPRM1 118/4885ACE 379/4885
US-20140088105-A1 Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists CRHR1, CRH, CRHR2 GHSR 18/4885OPRM1 61/4885ACE 303/4885
US-20100197705-A1 Quinazolinone Derivatives Useful as Vanilloid Antagonists KCNA4, KCNA3, KCNB1 GHSR 1602/4885OPRM1 171/4885ACE 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.